Levetiracetam Tablet, Film Coated
Product Images NDC 65162-538

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 65162-538). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracitam Tablets, Usp-figure07 (Levetiracetam Tablets Usp 1)

Text panel showing formulas for calculating creatinine clearance (CLcr) adjusted for age, weight, serum creatinine, and body surface area (BSA), including a factor adjustment for female patients and normalization to body surface area.*

FDA Label Image

23 (Levetiracetam Tablets Usp 10)

Label for Levetiracetam Tablets, USP 500 mg film-coated oral tablets. The package contains 120 tablets and is distributed by Amneal Pharmaceuticals LLC, Bridgewater, NJ. The label includes storage instructions, pharmacist dispensing advice, and a barcode. The tablets are illustrated as small and oval-shaped.*

FDA Label Image

26 (Levetiracetam Tablets Usp 11)

Levetiracetam Tablets, USP 750 mg film-coated tablets label by Amneal Pharmaceuticals LLC. The label states the dosage strength, quantity of 120 tablets, and provides storage instructions and pharmacist dispensing information. The label includes a barcode and NDC 65162-538-16.*

FDA Label Image

29 (Levetiracetam Tablets Usp 12)

Label for Levetiracetam Tablets, USP 1000 mg film-coated tablets. The label indicates a quantity of 60 tablets and is distributed by Amneal Pharmaceuticals LLC. It includes storage instructions, pharmacist dispensing information, and a barcode.*

FDA Label Image

9596f2fe-figure-01 (Levetiracetam Tablets Usp 2)

Chemical structure of levetiracetam, showing a pyrrolidone ring attached to an ethyl group and an amide functional group, consistent with the generic name levetiracetam.*

FDA Label Image

20 (Levetiracetam Tablets Usp 3)

Bar chart showing the percentage of patients by treatment group: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The y-axis represents the percentage of patients from 0% to 45%, highlighting higher patient percentages in Levetiracetam groups compared to placebo.*

FDA Label Image

14 (Levetiracetam Tablets Usp 4)

A bar graph showing the percentage of patients by treatment group: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The x-axis lists the groups with patient counts, and the y-axis indicates the percentage of patients. The chart compares patient response rates across these groups.*

FDA Label Image

Levetiracetam Tablets Usp 5

A bar graph displaying the percentage of patients with two groups: Placebo (N=104) at 14.4% and Levetiracetam 3000 mg/day (N=180) at 39.4%. The y-axis shows the percentage of patients from 0% to 45%. The Levetiracetam group shows a notably higher percentage compared to the placebo group.*

FDA Label Image

54 (Levetiracetam Tablets Usp 6)

A bar chart comparing the percentage of patients in two groups: Placebo (N=97) and Levetiracetam (N=101). The vertical axis shows the percentage of patients from 0% to 45%. The Levetiracetam group has a higher percentage at 44.6%, while the Placebo group is at 19.6%. An asterisk is present above the Levetiracetam bar, indicating statistical significance.*

FDA Label Image

78 (Levetiracetam Tablets Usp 7)

A bar chart comparing the percentage of patients for placebo (19.6%, N=51) and Levetiracetam (43.1%, N=58). The chart notes that the Levetiracetam value is statistically significant versus placebo. The vertical axis is labeled '% of Patients' ranging from 0% to 45%.*

FDA Label Image

10 (Levetiracetam Tablets Usp 8)

Bar chart comparing percentage of patients between Placebo and Levetiracetam groups. The chart shows 45.2% for Placebo (N=84) and 72.2% for Levetiracetam (N=79) on the vertical axis labeled % of Patients, with a significant difference indicated by an asterisk above the Levetiracetam bar.*

FDA Label Image

20 (Levetiracetam Tablets Usp 9)

Levetiracetam Tablets, USP 250 mg film-coated tablets label by Amneal Pharmaceuticals LLC. The label includes the NDC 65162-528-16, indicates a quantity of 120 tablets for oral use, and shows storage and pharmacist dispensing instructions. The Amneal logo is also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.